Danni Yu

715 total citations
20 papers, 419 citations indexed

About

Danni Yu is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Molecular Biology. According to data from OpenAlex, Danni Yu has authored 20 papers receiving a total of 419 indexed citations (citations by other indexed papers that have themselves been cited), including 13 papers in Oncology, 6 papers in Pulmonary and Respiratory Medicine and 5 papers in Molecular Biology. Recurrent topics in Danni Yu's work include Cancer Immunotherapy and Biomarkers (9 papers), Advanced Breast Cancer Therapies (3 papers) and Lung Cancer Research Studies (3 papers). Danni Yu is often cited by papers focused on Cancer Immunotherapy and Biomarkers (9 papers), Advanced Breast Cancer Therapies (3 papers) and Lung Cancer Research Studies (3 papers). Danni Yu collaborates with scholars based in United States, Spain and China. Danni Yu's co-authors include John C. Kraft, John Kauh, Anna M. Szpurka, Yu Gao, Rodney J. Y. Ho, Amita Patnaik, Maria J. de Miguel, Leena Gandhi, Yung‐Jue Bang and Muhammad Wasif Saif and has published in prestigious journals such as Nature Communications, Journal of Clinical Oncology and Cancer Research.

In The Last Decade

Danni Yu

19 papers receiving 415 citations

Peers

Countries citing papers authored by Danni Yu

Since Specialization

Citations

This map shows the geographic impact of Danni Yu's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Danni Yu with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Danni Yu more than expected).

Fields of papers citing papers by Danni Yu

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Danni Yu. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Danni Yu. The network helps show where Danni Yu may publish in the future.

Co-authorship network of co-authors of Danni Yu

This figure shows the co-authorship network connecting the top 25 collaborators of Danni Yu. A scholar is included among the top collaborators of Danni Yu based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Danni Yu. Danni Yu is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Manipulation of Wnt/β‐Catenin Signaling by Synthetic Frizzled Agonist and LRP Antagonist in Organoid Cultures and In Vivo 2025 ·Small Methods ·(unknown), Jiawen Wang, (unknown), Danni Yu, (unknown), Jinsong Wei, Xiaoyu Li, (unknown), (unknown), Bing Zhao	0
2	The regulatory T cell-selective interleukin-2 receptor agonist rezpegaldesleukin in the treatment of inflammatory skin diseases: two randomized, double-blind, placebo-controlled phase 1b trials 2024 ·Nature Communications ·Jonathan I. Silverberg, David Rosmarin, Raj Chovatiya, Thomas Bieber, Stephen M. Schleicher, Lisa A. Beck, Melinda Gooderham, Sohail S. Chaudhry, Christie Fanton, Danni Yu, Joshua Levy, (unknown), Takahiro Miyazaki, Mary Tagliaferri, Carsten Schmitz, Ajay Nirula, Brian L. Kotzin, Jonathan Zalevsky	12
3	205P Efficacy and safety of neoadjuvant chemotherapy with or without PD-L1/PD-1 inhibitors in surgically limited-stage small cell lung cancer 2024 ·ESMO Open ·Lin Shi, Zhihong Liu, Hua Li, Ling Guo, Jessica Tang, Danni Yu, Shuwei Zhou	1
4	Associations between KIR/KIR-ligand genotypes and clinical outcome for patients with advanced solid tumors receiving BEMPEG plus nivolumab combination therapy in the PIVOT-02 trial 2023 ·Cancer Immunology Immunotherapy ·(unknown), Amy K. Erbe, Jennifer Birstler, KyungMann Kim, Ute Hoch, Sue Currie, (unknown), Danni Yu, Arlene O. Siefker‐Radtke, Nizar M. Tannir, Sara M. Tolaney, Adi Diab, Paul M. Sondel	2
5	ARF1 maintains intestinal homeostasis by modulating gut microbiota and stem cell function 2023 ·Life Sciences ·Danni Yu, (unknown), Zixiang Wang, Steven X. Hou, Ling Sun	2
6	Bempegaldesleukin plus nivolumab in first-line renal cell carcinoma: results from the PIVOT-02 study 2022 ·Journal for ImmunoTherapy of Cancer ·Nizar M. Tannir, (unknown), Adi Diab, Mario Sznol, Mehmet Asım Bilen, Arjun Vasant Balar, Giovanni Grignani, Erika Puente-Poushnejad, (unknown), David Chien, Ute Hoch, (unknown), Danni Yu, Sue Currie, Mary Tagliaferri, Jonathan Zalevsky, Arlene O. Siefker‐Radtke, Michael E. Hurwitz	21
7	A phase 1b study of crenigacestat (LY3039478) in combination with gemcitabine and cisplatin or gemcitabine and carboplatin in patients with advanced or metastatic solid tumors 2022 ·Cancer Chemotherapy and Pharmacology ·Christophe Massard, Philippe A. Cassier, (unknown), (unknown), Eunice Yuen, Danni Yu, Gerard J. Oakley, Karim A. Benhadji, Shubham Pant	11
8	Bempegaldesleukin plus Nivolumab in First-line Metastatic Urothelial Carcinoma: Results from PIVOT-02 2022 ·European Urology ·Arlene O. Siefker‐Radtke, (unknown), Adi Diab, Mario Sznol, Mehmet Asım Bilen, Arjun Vasant Balar, Giovanni Grignani, Erika Puente-Poushnejad, (unknown), David Chien, Ute Hoch, (unknown), Danni Yu, Sue Currie, Mary Tagliaferri, Jonathan Zalevsky, Michael E. Hurwitz, Nizar M. Tannir	14
9	Blocking TIM-3 in Treatment-refractory Advanced Solid Tumors: A Phase Ia/b Study of LY3321367 with or without an Anti-PD-L1 Antibody 2021 ·Clinical Cancer Research ·James J. Harding, Víctor Moreno, Yung‐Jue Bang, Min Hee Hong, Amita Patnaik, José Trigo, Anna M. Szpurka, Noboru Yamamoto, Toshihiko Doi, Siqing Fu, Boris Calderón, Nieves Vélez de Mendizábal, Emiliano Calvo, Danni Yu, Leena Gandhi, (unknown), Violeta Régnier Galvão, Ching Ching Leow, Maria J. de Miguel	116
10	A phase 1b study of the Notch inhibitor crenigacestat (LY3039478) in combination with other anticancer target agents (taladegib, LY3023414, or abemaciclib) in patients with advanced or metastatic solid tumors 2021 ·Investigational New Drugs ·Analía Azaro, Christophe Massard, William D. Tap, Philippe A. Cassier, Jaime R. Merchan, Antoîne Italiano, (unknown), Eunice Yuen, Danni Yu, Gerard J. Oakley, Karim A. Benhadji, Shubham Pant	29
11	LY3022855, an anti–colony stimulating factor-1 receptor (CSF-1R) monoclonal antibody, in patients with advanced solid tumors refractory to standard therapy: phase 1 dose-escalation trial 2021 ·Investigational New Drugs ·Afshin Dowlati, R. Donald Harvey, Richard D. Carvajal, Omid Hamid, Samuel J. Klempner, John Kauh, Daniel A. Peterson, Danni Yu, Sonya C. Chapman, Anna M. Szpurka, (unknown), Tonya Quinlan, Robert Wesolowski	35
12	Safety and Clinical Activity of a New Anti-PD-L1 Antibody as Monotherapy or Combined with Targeted Therapy in Advanced Solid Tumors: The PACT Phase Ia/Ib Trial 2020 ·Clinical Cancer Research ·Amita Patnaik, Timothy A. Yap, Hyun Cheol Chung, Maria J. de Miguel, Yung‐Jue Bang, Chia‐Chi Lin, Wu‐Chou Su, Antoîne Italiano, Kay Hoong Chow, Anna M. Szpurka, Danni Yu, Yumin Zhao, (unknown), (unknown), Burkhard Vangerow, Leena Gandhi, Xiaojian Xu, Johanna C. Bendell	31
13	Phase 1 study of LY3022855, a colony-stimulating factor-1 receptor (CSF-1R) inhibitor, in patients with metastatic breast cancer (MBC) or metastatic castration-resistant prostate cancer (MCRPC). 2019 ·Journal of Clinical Oncology ·Karen A. Autio, Christopher A. Klebanoff, David Schaer, John Kauh, Susan F. Slovin, Victoria Blinder, Elizabeth Comen, Daniel C. Danila, David Hoffman, (unknown), Philomena McAndrew, Shanu Modi, Michael J. Morris, Dana E. Rathkopf, Rachel Sanford, Sonya C. Tate, Danni Yu, Heather L. McArthur	16
14	Recent developments of nanotherapeutics for targeted and long-acting, combination HIV chemotherapy 2018 ·European Journal of Pharmaceutics and Biopharmaceutics ·Yu Gao, John C. Kraft, Danni Yu, Rodney J. Y. Ho	44
15	Abstract CT018: Interim safety and clinical activity in patients (pts) with advanced refractory solid tumors from a phase Ia/b study investigating the novel anti-PD-L1 antibody (LY3300054) administered alone or in combination with other agents 2018 ·Cancer Research ·Amita Patnaik, Yung‐Jue Bang, Hyun Cheol Chung, Maria J. de Miguel, Timothy A. Yap, Leijun Hu, Anna M. Szpurka, Danni Yu, Anindya Chatterjee, Shivani Nanda, Burkhard Vangerow, Mythili Koneru, Johanna C. Bendell	2
16	A phase I study of LY3022855, a colony-stimulating factor-1 receptor (CSF-1R) inhibitor, in patients (pts) with advanced solid tumors. 2017 ·Journal of Clinical Oncology ·Afshin Dowlati, Hope S. Rugo, R. Donald Harvey, Ragini R. Kudchadkar, Richard D. Carvajal, Gulam A. Manji, Omid Hamid, Samuel J. Klempner, Shande Tang, Danni Yu, John Kauh, David Schaer, Sonya C. Tate, Robert Wesolowski	7
17	A first-in-human dose phase 1 study of LY3009120 in advanced cancer patients. 2017 ·Journal of Clinical Oncology ·David S. Hong, Antoine Hollebecque, Michael S. Gordon, Keith T. Flaherty, Geoffrey I. Shapiro, Jordi Rodón, Michael Millward, (unknown), Wei Zhang, Ling Gao, (unknown), Melinda D. Willard, Danni Yu, Andrew E. Schade, Daniel L. Flynn, Michael D. Kaufman, Sheng-Bin Peng, Ilaria Conti, Ramón V. Tiu, Ryan J. Sullivan	6
18	Phase 1 study of the anti-vascular endothelial growth factor receptor 3 monoclonal antibody LY3022856/IMC-3C5 in patients with advanced and refractory solid tumors and advanced colorectal cancer 2016 ·Cancer Chemotherapy and Pharmacology ·Muhammad Wasif Saif, James A. Knost, E. Gabriela Chiorean, (unknown), Danni Yu, Bronislaw Pytowski, Amy Qin, John Kauh, Bert H. O’Neil	56
19	Phase I study of anti-VEGF receptor-3 (VEGFR-3) monoclonal antibody (mab) LY3022856/IMC-3C5 (3C5). 2015 ·Journal of Clinical Oncology ·(unknown), James A. Knost, E. Gabriela Chiorean, (unknown), Danni Yu, Bronislaw Pytowski, Amy Qin, John Kauh, Bert H. O’Neil	2
20	Proteomic analysis of high NaCl-induced changes in abundance of nuclear proteins 2012 ·Physiological Genomics ·Jinxi Li, Joan D. Ferraris, Danni Yu, (unknown), Yuichiro Izumi, Guanghui Wang, Marjan Guček, Maurice B. Burg	12

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact